The current approaches of metastatic breast cancer treatment are tyrosine kinase inhibitor (lapatinib); PARP inhibitors with BRCA1 or BRCA2 gene mutation; CDK4/6 inhibitor (palbociclib); PI3 kinase inhibitors; and immunotherapy (“checkpoint inhibitors”). Here, BRCA2 is linked to breast carcinoma.